The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
Revised 9/27/18: The term "immediate-release" was changed to "short-acting" throughout the article to more accurately describe the pharmacokinetics of Roxybond.

The FDA has approved Roxybond (Daiichi Sankyo), a short-acting (SA) oxycodone formulation with abuse-deterrent properties, for treatment of pain requiring management with an opioid. Roxybond is the first SA opioid to be approved as an abuse-deterrent product. Oxaydo, another SA oxycodone formulation, has properties that discourage its intranasal and intravenous use, but is not considered an abuse-deterrent product by the FDA. Use of opioids for treatment of pain was reviewed in a recent issue.1

ABUSE-DETERRENT OPIOIDS — Abuse-deterrent opioid formulations have properties that make their intentional nontherapeutic use more difficult, less attractive, and less rewarding, but they are expensive, and whether they reduce overall opioid abuse remains to be determined. No oral opioid formulation prevents consumption of intact dosage units. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1555
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian